TOKYO and CAMBRIDGE, England, Nov. 2, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has entered into an agreement1 with Tempero Bio, under which Tempero Bio has in-licensed exclusive global rights to Sosei Heptares' mGlu5 negative allosteric modulator (NAM)...
Read More Details
Finally We wish PressBee provided you with enough information of ( Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases )
Also on site :